Moderna shares extend rally after Phase 3 melanoma results
Moderna (MRNA) shares rose 8.18% to $157.53, extending a month-long rally tied to Phase 3 melanoma trial results reported with Merck (MRK).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.